nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.03.2014 | NON-THEMATIC REVIEW

The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy

verfasst von: Hai Wang, Yu-Chen Du, Xiao-jun Zhou, Hong Liu, Shou-Ching Tang

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

The major functions of Hippo (Hpo) signaling pathway are to control cell growth, proliferation, and apoptosis. As its important downstream player, yes-associated protein (YAP)-1 was originally found to promote cell proliferation and transformation. Overexpression of YAP-1 has been linked to tumor progression and worse survival in certain malignancies. However, it has been recently recognized as a tumor suppressor gene as well since it also induces apoptosis. Decreased or absent expression of YAP-1 is highly correlated with tumor progression and worse survival in other tumors such as breast cancer. It is clear that YAP-1 plays a dual role as oncogene and tumor suppressor gene in human oncogenesis, depending on the specific tissue type involved. Here, we reviewed the recent research on both the oncogenic and tumor suppressor function of YAP-1 and its significance in human malignancy. The clinical implication of YAP-1 expression in cancer prognosis and the development of targeted therapy will also be discussed.

Zhao, B., et al. (2013). The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal. Nature Cell Biology, 13, 877–883.CrossRef

Zhou, D., et al. (2011). Mst1 and Mst2 protein kinases restrain intestinal stem cell proliferation and colonic tumorigenesis by inhibition of Yes-associated protein (Yap) overabundance. Proceedings of the National Academy of Sciences of the United States of America, 108, E1312–E1320.PubMedCrossRefPubMedCentral

Tamm, C., et al. (2011). Regulation of mouse embryonic stem cell self-renewal by a Yes-YAP-TEAD2 signaling pathway downstream of LIF. Journal of Cell Science, 124, 1136–1144.PubMedCrossRef

Zhang, H., et al. (2011). Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin. Proceedings of the National Academy of Sciences of the United States of America, 108, 2270–2275.PubMedCrossRefPubMedCentral

Yu, F. X., et al. (2012). Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell, 150(4), 780–791.PubMedCrossRefPubMedCentral

Zhao, B., et al. (2007). Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes and Development, 21, 2747–2761.PubMedCrossRefPubMedCentral

Lapi, E., et al. (2008). PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Molecular Cell, 32, 803–814.PubMedCrossRef

Strano, S., et al. (2007). The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA damage. Molecular Cell, 18, 447–459.CrossRef

Yuan, M., et al. (2008). Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death and Differentiation, 15, 1752–1759.PubMedCrossRef

10.

Bertini, E. (2009). YAP: at the crossroad between transformation and tumor suppression. Cell Cycle, 8, 49–57.PubMedCrossRef

11.

Zender, L., et al. (2006). Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell, 125, 1253–1267.PubMedCrossRefPubMedCentral

12.

Overholtzer, M., et al. (2006). Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proceedings of the National Academy of Sciences of the United States of America, 103, 12405–12410.PubMedCrossRefPubMedCentral

13.

Zhao, B., et al. (2008). TEAD mediates YAP-dependent gene induction and growth control. Genes and Development, 22, 1962–1971.PubMedCrossRefPubMedCentral

14.

Barry, E. R., et al. (2013). Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature, 493, 106–110.PubMedCrossRefPubMedCentral

15.

Hao, Y., et al. (2008). Tumor suppressor LATS1 is a negative regulator of oncogene YAP. Journal of Biological Chemistry, 283, 5496–5509.PubMedCrossRef

16.

Oka, T., et al. (2008). Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). Journal of Biological Chemistry, 283, 27534–27546.PubMedCrossRef

17.

Ren, F. L., et al. (2010). Hippo signaling regulates Yorkie nuclear localization and activity through 14-3-3 dependent and independent mechanisms. Developmental Biology, 337, 303–312.PubMedCrossRefPubMedCentral

18.

Zhao, B., et al. (2010). A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes and Development, 24, 72–85.PubMedCrossRefPubMedCentral

19.

Basu, S., et al. (2003). Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Molecular Cell, 11, 11–23.PubMedCrossRef

20.

Zhao, B., et al. (2011). Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes and Development, 25, 51–63.PubMedCrossRefPubMedCentral

21.

Oka, T., et al. (2010). Functional complexes between YAP2 and ZO-2 are PDZ domain-dependent, and regulate YAP2 nuclear localization and signalling. The Biochemical Journal, 432, 461–472.PubMedCrossRef

22.

Remue, E., et al. (2010). TAZ interacts with zonula occludens-1 and -2 proteins in a PDZ-1 dependent manner. FEBS Letters, 584, 4175–4180.PubMedCrossRef

23.

Wu, S., et al. (2003). Hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell, 114, 445–456.PubMedCrossRef

24.

Harvey, K. F., et al. (2003). The Drosophila Mst ortholog, hippo, restricts growth and cell proliferation and promotes apoptosis. Cell, 114, 457–467.PubMedCrossRef

25.

Callus, B. A., et al. (2006). Association of mammalian sterile twenty kinases, Mst1 and Mst2, with hSalvador via C-terminal coiled-coil domains, leads to its stabilization and phosphorylation. The FEBS Journal, 273, 4264–4276.PubMedCrossRef

26.

Chan, E. H., et al. (2005). Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene, 24, 2076–2086.PubMedCrossRef

27.

Praskova, M., et al. (2008). MOBKL1A/MOBKL1B phosphorylation by MST1 and MST2 inhibits cell proliferation. Current Biology: CB, 18, 311–321.PubMedCrossRef

28.

Oka, T. V., et al. (2008). Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP). Journal of Biological Chemistry, 283, 27534–27546.PubMedCrossRef

29.

Zhang, L., et al. (2008). The TEAD/TEF family of transcription factor Scalloped mediates Hippo signaling in organ size control. Developmental Cell, 14, 377–387.PubMedCrossRefPubMedCentral

30.

Wu, S., et al. (2008). The TEAD/TEF family protein Scalloped mediates transcriptional output of the Hippo growth-regulatory pathway. Developmental Cell, 14(2008), 388–398.PubMedCrossRef

31.

Ziosi, M., et al. (2010). dMyc functions downstream of Yorkie to promote the supercompetitive behavior of hippo pathway mutant cells. PLoS Genetics, 6(9), e1001140. doi:10.1371/journal.pgen.1001140.PubMedCrossRefPubMedCentral

32.

Neto-Silva, R. M., et al. (2010). Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the Drosophila homolog of Yap. Developmental Cell, 19, 507–520.PubMedCrossRefPubMedCentral

33.

Zhang, J., et al. (2009). YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nature Cell Biology, 11, 1444–1450.PubMedCrossRefPubMedCentral

34.

Alarcon, C., et al. (2009). Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell, 139, 757–769.PubMedCrossRefPubMedCentral

35.

Vitolo, M. I., et al. (2007). The RUNX2 transcription factor cooperates with the YES-associated protein, YAP65, to promote cell transformation. Cancer Biology & Therapy, 6, 856–863.CrossRef

36.

Komuro, A., et al. (2003). WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. Journal of Biological Chemistry, 278, 33334–33341.

37.

Strano, S., et al. (2001). Physical interaction with Yes-associated protein enhances p73 transcriptional activity. Journal of Biological Chemistry, 276, 15164–15173.PubMedCrossRef

38.

Lamar, J. M., et al. (2012). The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proceedings of the National Academy of Sciences of the United States of America, 109, E2441–E2450.PubMedCrossRefPubMedCentral

39.

Xu, M. Z., et al. (2011). AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene, 30, 1229–1240.PubMedCrossRefPubMedCentral

40.

Ehsanian, R., et al. (2010). YAP dysregulation by phosphorylation or DeltaNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene, 29, 6160–6171.PubMedCrossRefPubMedCentral

41.

Yu,S.J., et al. (2013). MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clinical Cancer Research, 19, 1389–1399.

42.

Espanel, X., et al. (2001). Yes-associated protein and p53-binding protein-2 interact through their WW and SH3 domains. Journal of Biological Chemistry, 276, 14514–14523.PubMed

43.

Danovi, S. A., et al. (2008). Yes-associated protein (YAP) is a critical mediator of c-Jun-dependent apoptosis. Cell Death and Differentiation, 15, 217–219.PubMedCrossRef

44.

Levy, D., et al. (2008). Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. Molecular Cell, 29, 350–361.PubMedCrossRef

45.

Levy, D., et al. (2007). The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell Death and Differentiation, 14, 743–751.

46.

Okazaki, T., et al. (2012). Up-regulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73/YAP-mediated apoptosis in glioblastoma. Cancer Letters, 323, 199–207.PubMedCrossRef

47.

Yee, K.S., et al. (2012). A RASSF1A polymorphism restricts p53/p73 activation and associates with poor survival and accelerated age of onset of soft tissue sarcoma. Cancer Research, 72, 2206–2217.

48.

Matallanas, D., et al. (2007). RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Molecular Cell, 27, 962–975.PubMedCrossRefPubMedCentral

49.

Camargo, F. D., et al. (2007). YAP1 increases organ size and expands undifferentiated progenitor cells. Current Biology, 17(23), 2054–2060.PubMedCrossRef

50.

Lian, I., et al. (2010). The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes & Development, 24(11), 1106–1118.CrossRef

51.

52.

Varelas, X., et al. (2010). The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. Developmental Cell, 19, 831–844.PubMedCrossRef

53.

Yi, C., et al. (2010). Merlin in organ size control and tumorigenesis: hippo versus EGFR? Genes and Development, 24, 1673–1679.PubMedCrossRefPubMedCentral

54.

Fan, R., et al. (2013). Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1. Proceedings of the National Academy of Sciences of the United States of America, 110(7), 2569–2574.PubMedCrossRefPubMedCentral

55.

Fernandez, L. A., et al. (2009). YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes and Development, 23, 2729–2741.CrossRef

56.

Tumaneng, K., et al. (2012). YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nature Cell Biology, 14, 1322–1329.PubMedCrossRef

57.

Rosenbluh, J., et al. (2012). â-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell, 151(7), 1457–1473.PubMedCrossRefPubMedCentral

58.

Tschaharganeh, D. F., et al. (2013). Yes-associated protein up-regulates Jagged-1 and activates the Notch pathway in human hepatocellular carcinoma. Gastroenterology, 144(7), 1530–1542.PubMedCrossRef

59.

Muramatsu, T., et al. (2011). YAP is a candidate oncogene for esophageal squamous cell carcinoma. Carcinogenesis, 32, 389–398.PubMedCrossRef

60.

Imoto, I., et al. (2001). Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas. Cancer Research, 61, 6629–6634.PubMed

61.

Liu, T., et al. (2013). Clinical significance of yes-associated protein overexpression in cervical carcinoma: the differential effects based on histotypes. International Journal of Gynecological Cancer, 23, 735–742.PubMedCrossRef

62.

Tang, S.C., et al. (2002). BAG-1, an anti-apoptotic tumour marker. IUBMB Life, 53, 99–105.

63.

Tang, S. C., et al. (1999). Expression of BAG-1 in invasive breast carcinomas. Journal of Clinical Oncology, 17, 1710–1719.PubMed

64.

Turner, B. C., et al. (2001). BAG-1: a novel biomarker predicting long-term survival in early-stage breast cancer. Journal of Clinical Oncology, 19, 992–1000.PubMed

65.

Xu, M. Z., et al. (2009). Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer, 115, 4576–4585.PubMedCrossRefPubMedCentral

66.

Song, M., et al. (2012). Nuclear expression of Yes-associated protein 1 correlates with poor prognosis in intestinal type gastric cancer. Anticancer Research, 32, 3827–3834.PubMed

67.

Wang, Y., et al. (2010). Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Science, 101, 1279–1285.PubMedCrossRef

68.

Su, L. L., et al. (2012). Expression of Yes-associated protein in non-small cell lung cancer and its relationship with clinical pathological factors. Chinese Medical Journal, 125, 4003–4008.PubMed

69.

Carter, S. L., et al. (1994). Loss of heterozygosity at 11q22-q23 in breast cancer. Cancer Research, 54, 6270–6274.PubMed

70.

Winqvist, R., et al. (1995). Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Research, 55, 2660–2664.PubMed

71.

Gudmundsson, J., et al. (1995). Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. British Journal of Cancer, 72, 696–701.PubMedCrossRefPubMedCentral

72.

Hampton, G. M., et al. (1994). Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Research, 54, 4586–4589.PubMed

73.

Tomlinson, I. P., et al. (1995). Loss of heterozygosity on chromosome 11 q in breast cancer. Journal of Clinical Pathology, 48, 424–428.PubMedCrossRefPubMedCentral

74.

Tufail, R., et al. (2012). Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. Breast Cancer Research and Treatment, 131, 743–750.PubMedCrossRefPubMedCentral

75.

Wang, Y., et al. (2013). Clinical and prognostic significance of Yes-associated protein in colorectal cancer. Tumour Biology, 34(4), 2169–2174.PubMedCrossRef

76.

Fujii, M., et al. (2012). Exploration of a new drug that targets YAP. Journal of Biochemistry, 152(3), 209–211.PubMedCrossRef

77.

Bao, Y., et al. (2011). A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. Journal of Biochemistry, 150(2), 199–208.PubMedCrossRef

Titel: The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy
verfasst von: Hai Wang
Yu-Chen Du
Xiao-jun Zhou
Hong Liu
Shou-Ching Tang
Publikationsdatum: 01.03.2014
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 1/2014
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-013-9463-3

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

The dual functions of YAP-1 to promote and inhibit cell growth in human malignancy

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Systemic therapeutic strategies for GEP-NETS: what can we expect in the future?

Adoptive immunotherapy of metastatic breast cancer: present and future

Why anti-Bcl-2 clinical trials fail: a solution

Dietary phytochemicals alter epigenetic events and signaling pathways for inhibition of metastasis cascade

Biological insights into effective and antagonistic combinations of targeted agents with chemotherapy in solid tumors

Oxygen regulates molecular mechanisms of cancer progression and metastasis

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie